Real-world evidence on treatment switching in patients with moderate-to-severe ulcerative colitis: a systematic review of literature

被引：1
|
作者：
Singh, H. [1 ]
Wilson, L. [2 ]
Pandey, A. [3 ]
Tencer, 'T. [4 ]
Kumar, J. [4 ]
机构：
[1] Amaris Consulting Ltd, Hlth Econ & Market Access HEMA, Toronto, ON, Canada
[2] Amaris Consulting Ltd, Hlth Econ & Market Access HEMA, Shanghai, Peoples R China
[3] Amaris Consulting Ltd, Hlth Econ & Market Access HEMA, London, England
[4] Bristol Myers Squibb, Global HEOR, Princeton, NJ USA
来源：
JOURNAL OF CROHNS & COLITIS | 2021年 / 15卷
关键词：
D O I：
10.1093/ecco-jcc/jjab076.661
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P540
引用
收藏
页码：S511 / S512
页数：3
相关论文
共 50 条
  • [1] REAL-WORLD DOSE ESCALATION IN PATIENTS WITH MODERATE-TO-SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW OF LITERATURE
    Singh, Harpreet
    Pandey, Anuja
    Wilson, Liam
    Tencer, Tom
    Kumar, Jinender
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S26 - S26
  • [2] Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review
    Irving, Peter M.
    Hur, Peter
    Gautam, Raju
    Guo, Xiang
    Vermeire, Severine
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2024, 30 (09): : 1026 - 1040
  • [3] Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
    Singh, Harpreet
    Wilson, Liam
    Tencer, Tom
    Kumar, Jinender
    [J]. CLINICOECONOMICS AND OUTCOMES RESEARCH, 2023, 15 : 125 - 138
  • [4] Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis (UC): evidence from a systematic literature review (SLR)
    Irving, P. M.
    Hur, P.
    Gautam, R.
    Guo, X.
    Vermeire, S.
    [J]. JOURNAL OF CROHNS & COLITIS, 2023, 17 : 739 - 740
  • [5] Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data
    Xiao, Y.
    Lakatos, P. L.
    Bourdages, R.
    Bitton, A.
    Afif, W.
    Kohen, R.
    Berberi, M.
    Bessissow, T.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S445 - S445
  • [6] Dose escalation and switching of biologics in ulcerative colitis: a systematic literature review in real-world evidence
    Gemayel, Nathalie C.
    Rizzello, Eugenio
    Atanasov, Petar
    Wirth, Daniel
    Borsi, Andras
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2019, 35 (11) : 1911 - 1923
  • [7] CANADIAN REAL-WORLD EVIDENCE ON EPIDEMIOLOGY, OUTCOMES AND ECONOMICS OF MODERATE-TO-SEVERE OSTEOARTHRITIS: A SYSTEMATIC LITERATURE REVIEW
    Larkin-Kaiser, K.
    Waters-Banker, C.
    Cowling, T.
    Snow, L. A.
    Hasani, I
    Fernet, M.
    [J]. VALUE IN HEALTH, 2019, 22 : S707 - S707
  • [8] Efficacy and safety of tofacitinib in patients with moderate-to-severe ulcerative colitis: A real-world retrospective study
    Yoshimura, N.
    Okano, Soh
    Sako, Minako
    Takazoe, Masakazu
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S545 - S545
  • [9] Real-World Patterns and Economic Burden Associated With Treatment Failure With Advanced Therapies in Patients With Moderate-to-Severe Ulcerative Colitis
    Lee, Scott D.
    Betts, Keith A.
    Du, Ella Xiaoyan
    Nie, Xiaoyu
    Gupte-Singh, Komal
    Ritter, Timothy
    [J]. CROHNS & COLITIS 360, 2024, 6 (02)
  • [10] Real-World Patient Experience of Switching Biologic Treatment in Inflammatory Arthritis and Ulcerative Colitis - A Systematic Literature Review
    Luttropp, Karin
    Dalen, Johan
    Svedbom, Axel
    Dozier, Mary
    Black, Christopher M.
    Puenpatom, Amy
    [J]. PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 309 - 320
12345